CD8A and cancer: Furthermore, anti-CTLA-4 therapy alone and/or with anti-PD-1 treatment has been shown to offer important therapeutic benefits to cancer patients [124], and it enhances antitumor immune activity due to an increase in the number of CD8+ and CD4+ TILs.